Korean J Gastroenterol.
2022 Sep;80(3):161-162. 10.4166/kjg.2022.105.
Association of Hepatocellular Carcinoma Risk with Baseline Viral Load in HBeAg-positive Chronic Hepatitis B Patients under Antiviral Treatment
- Lee M
1,2
- Affiliations
-
- 1Department of Internal Medicine, Ewha Womans University College of Medicine , Seoul, Korea
- 2Department of Internal Medicine, Ewha Womans University Seoul Hospital , Seoul, Korea
- KMID: 2533321
- DOI: http://doi.org/10.4166/kjg.2022.105
Reference
-
1. Choi WM, Kim GA, Choi J, Han S, Lim YS. 2022; Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B. J Clin Invest. 132:e154833. DOI: 10.1172/JCI154833. PMID: 35358094. PMCID: PMC9106348.2. Chen CJ, Yang HI, Su J, et al. 2006; Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 295:65–73. DOI: 10.1001/jama.295.1.65. PMID: 16391218.3. Jang H, Yoon JS, Park SY, et al. 2022; Impact of HBeAg on hepatocellular carcinoma risk during oral antiviral treatment in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 20:1343–1353.e16. DOI: 10.1016/j.cgh.2021.09.001. PMID: 34500103.
